Novo Nordisk to research oral obesity treatment; Dana-Farber taps into Harbour BioMed’s mice platform in multiyear deal

Novo Nordisk and Lumen Bioscience have entered a research collaboration to explore R&D and manufacturing within obesity and other metabolic disorders, the companies announced Wednesday.

The collaboration builds off of research surrounding an orally delivered drug for the GI tract that can be manufactured with more...

Click to view original post